- Circulating biomarkers present great potential for minimally invasive diagnostics
- System contains 8 modules that detect a range of biomarkers from blood samples
- Can be developed to generate early diagnostic information for almost any condition
A modular and fully automated system for detecting a range of biomarkers has been invented. The novel Universal Molecular Processing System (uMPS) processes whole blood to concentrate clinically relevant biomarkers to nL volumes. The concentrated sample then passes through 8 modules that use various strategies to search for and analyze assorted biomarkers.
Desired cells are first isolated from a blood sample via antibodies covalently attached to Module 1. Modules 2 and 3 isolate plasma and solid-phase extract a selection of free molecules. Module 4 affinity selects nanovesicles (such as exosomes) and Module 5 counts single cells. Modules 6, 7, and 8 solid-phase extract and enrich DNA/RNA from lysed cells, purify the reaction products, and use a nanosensor to analyze the extracted DNA/RNA. Analysis can be any of a variety of assays: detecting a mutation, determining methylation patterns, profiling mRNA expression, or DNA/RNA sequencing. This technology can be developed to provide early diagnostic information and help guide clinical strategies for nearly any disease. Iterative data compilation and analysis can generate continuous improvements to further identify early biomarkers and, combined with outcome data, improve clinical strategies. The device has been used on stroke patients and pancreatic cancer patients to identify key biomarkers associated with each condition.
This technology is available for nonexclusive licensing only.
Number:US10393726B2 and US10830757B2
Name: Jackie Quay